Calendar · pharmadog

Sign In Subscribe

Week of Feb 23, 2026

50

Feb 23, 2026approval188d agoBRIVARACETAM — FDA approvalBRIVARACETAM

Sponsor: MICRO LABS. Form: SOLUTION. Route: INTRAVENOUS

full page →BRIVARACETAM →fda approvals ↗

Feb 23, 2026approval188d agoBRIVARACETAM — FDA approvalBRIVARACETAM

Sponsor: MSN. Form: SOLUTION. Route: INTRAVENOUS

full page →BRIVARACETAM →fda approvals ↗

Feb 23, 2026approval188d agoIPRATROPIUM BROMIDE — FDA approvalArmstrong Pharmaceuticals Inc

Sponsor: ARMSTRONG PHARMS. Form: AEROSOL, METERED. Route: INHALATION

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoTOPIRAMATE — FDA approvalLP Pharmaceutical (Xiamen) Co Ltd

Sponsor: SUN PHARM INDS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoPREGABALIN — FDA approvalViatris Inc

Sponsor: ALKEM LABS LTD. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoBRIVARACETAM — FDA approvalUCB SA

Sponsor: ZHEJIANG POLY PHARM. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoDILTIAZEM HYDROCHLORIDE — FDA approvalZydus Therapeutics Inc

Sponsor: ZYDUS PHARMS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoDILTIAZEM HYDROCHLORIDE — FDA approvalZydus Therapeutics Inc

Sponsor: ZYDUS PHARMS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoBRIVARACETAM — FDA approvalUCB SA

Sponsor: ALKEM LABS LTD. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

Feb 23, 2026approval188d agoSUSTOL (GRANISETRON) — FDA approvalgranisetron ER

Sponsor: HERON THERAPS INC. Form: INJECTABLE. Route: SUBCUTANEOUS

full page →granisetron ER →fda approvals ↗

Feb 23, 2026approval188d agoPREGABALIN — FDA approvalPREGABALIN

Sponsor: LUPIN LTD. Form: CAPSULE. Route: ORAL

full page →PREGABALIN →fda approvals ↗

Feb 23, 2026approval188d agoPREGABALIN — FDA approvalPREGABALIN

Sponsor: LUPIN LTD. Form: CAPSULE. Route: ORAL

full page →PREGABALIN →fda approvals ↗

Feb 23, 2026approval188d agoLOARGYS (PEGZILARGINASE-NBLN) — FDA approvalpegzilarginase

Sponsor: IMMEDICA PHARMA AB. Form: Injectable. Route: Injection

full page →pegzilarginase →fda approvals ↗

Feb 23, 2026grant188d agoUNIVERSITY OF NORTH DAKOTA — Indigenous Determinants of Prenatal Substance Use

GM grant. $84,940. PI: June-Yung Kim

full page →nih reporter ↗

Feb 23, 2026grant188d agoROCKEFELLER UNIVERSITY — Elucidating the host and viral determinants of treatment response in chronic ...

AI grant. $862,748. PI: Ype Peter De Jong

full page →nih reporter ↗

Feb 23, 2026grant188d agoUNIVERSITY OF PITTSBURGH AT PITTSBURGH — Skin-Targeted Metal-Organic Framework-Based Subunit Vaccines

AI grant. $437,250. PI: Emrullah Korkmaz

full page →nih reporter ↗

Feb 23, 2026grant188d agoUNIV OF MARYLAND, COLLEGE PARK — Regulation of Heme Adaptation in the Group A Streptococcus

AI grant. $417,295. PI: Kevin S. McIver

full page →nih reporter ↗

Feb 23, 2026grant188d agoTUFTS UNIVERSITY BOSTON — Role of CLCC1 in herpesvirus nuclear egress

AI grant. $243,600. PI: Ekaterina Heldwein

full page →nih reporter ↗

Feb 23, 2026grant188d agoMASSACHUSETTS GENERAL HOSPITAL — Ex-Vivo Machine Perfusion To Promote Tolerance Induction in Deceased Donor Ki...Massachusetts General Hospital

AI grant. $416,622. PI: Alban Longchamp

full page →nih reporter ↗

Feb 23, 2026grant188d agoGORDON RESEARCH CONFERENCES — 2026 Marine Natural Products Gordon Research Conference and Gordon Research S...

AT grant. $29,965. PI: Marcy J Balunas

full page →nih reporter ↗

Feb 23, 2026grant188d agoBOSTON UNIVERSITY (CHARLES RIVER CAMPUS) — Neurovascular Imaging Across Scales in Animals and Humans

NS grant. $250,000. PI: Thomas G Bifano

full page →nih reporter ↗

Feb 23, 2026grant188d agoUNIVERSITY OF MASSACHUSETTS AMHERST — Inhibiting Chikungunya Virus Protease using MTase-like Domain Interactions fo...University of Massachusetts

AI grant. $632,994. PI: Jeanne Ann Hardy

full page →nih reporter ↗

Feb 23, 2026grant188d agoJOHNS HOPKINS UNIVERSITY — Mechanisms of hair cell mechanotransductionJohns Hopkins University

DC grant. $687,094. PI: Ulrich Mueller

full page →nih reporter ↗

Feb 24, 2026approval187d agoROBINUL (GLYCOPYRROLATE) — FDA approvalGLYCOPYRROLATE

Sponsor: HIKMA. Form: INJECTABLE. Route: INJECTION

full page →GLYCOPYRROLATE →fda approvals ↗

Feb 24, 2026approval187d agoCLOMIPHENE CITRATE — FDA approvalCLOMIPHENE CITRATE

Sponsor: COSETTE. Form: TABLET. Route: ORAL

full page →CLOMIPHENE CITRATE →fda approvals ↗

Feb 24, 2026approval187d agoLURASIDONE HYDROCHLORIDE — FDA approvalSumitomo Pharma America Inc

Sponsor: CHARTWELL RX. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 24, 2026approval187d agoLURASIDONE HYDROCHLORIDE — FDA approvalSumitomo Pharma America Inc

Sponsor: CHARTWELL RX. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 24, 2026approval187d agoMICAFUNGIN SODIUM — FDA approvalMICAFUNGIN SODIUM

Sponsor: YICHANG HUMANWELL. Form: INJECTABLE. Route: INTRAVENOUS

full page →MICAFUNGIN SODIUM →fda approvals ↗

Feb 24, 2026approval187d agoFOLLISTIM AQ (FOLLITROPIN ALFA/BETA) — FDA approvalfollitropin beta

Sponsor: ORGANON USA LLC. Form: INJECTABLE. Route: SUBCUTANEOUS

full page →follitropin beta →fda approvals ↗

Feb 24, 2026approval187d agoFINGOLIMOD HYDROCHLORIDE — FDA approvalFINGOLIMOD HYDROCHLORIDE

Sponsor: AUROBINDO PHARMA LTD. Form: CAPSULE. Route: ORAL

full page →FINGOLIMOD HYDROCHLORIDE →fda approvals ↗

Feb 24, 2026approval187d agoLIRAGLUTIDE — FDA approvalSaxenda

Sponsor: BIOCON PHARMA. Form: SOLUTION. Route: SUBCUTANEOUS

full page →Saxenda →fda approvals ↗

Feb 24, 2026approval187d agoBRAFTOVI (ENCORAFENIB) — FDA approvalencorafenib

Sponsor: ARRAY BIOPHARMA INC. Form: CAPSULE. Route: ORAL

full page →encorafenib →fda approvals ↗

Feb 24, 2026approval187d agoBRAFTOVI (ENCORAFENIB) — FDA approvalencorafenib

Sponsor: ARRAY BIOPHARMA INC. Form: CAPSULE. Route: ORAL

full page →encorafenib →fda approvals ↗

Feb 24, 2026approval187d agoPREGABALIN — FDA approvalViatris Inc

Sponsor: FOURRTS LABS. Form: CAPSULE. Route: ORAL

full page →fda approvals ↗

Feb 24, 2026approval187d agoMUPIROCIN — FDA approvalFougera Pharmaceuticals Inc

Sponsor: FOUGERA PHARMS. Form: OINTMENT. Route: TOPICAL

full page →fda approvals ↗

Feb 24, 2026approval187d agoMUPIROCIN — FDA approvalFougera Pharmaceuticals Inc

Sponsor: FOUGERA PHARMS. Form: OINTMENT. Route: TOPICAL

full page →fda approvals ↗

Feb 24, 2026approval187d agoMUPIROCIN — FDA approvalFougera Pharmaceuticals Inc

Sponsor: FOUGERA PHARMS. Form: OINTMENT. Route: TOPICAL

full page →fda approvals ↗

Feb 24, 2026approval187d agoGABAPENTIN — FDA approvalAlmatica Pharma LLC

Sponsor: IPCA LABS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Feb 24, 2026approval187d agoLIRAGLUTIDE — FDA approvalNovo Nordisk Inc

Sponsor: ORBICULAR. Form: SOLUTION. Route: SUBCUTANEOUS

full page →fda approvals ↗

Feb 24, 2026grant187d agoWASHINGTON UNIVERSITY — Dissecting the Impact of HIV-Induced Immunometabolic Perturbation on Tubercul...

AI grant. $427,623. PI: George Kyei

full page →nih reporter ↗

Feb 24, 2026grant187d agoUNIVERSITY OF CONNECTICUT STORRS — Role of Alternate Ribosome Binding in Pathogenesis

AI grant. $447,604. PI: VICTORIA L ROBINSON

full page →nih reporter ↗

Feb 24, 2026grant187d agoUNIVERSITY OF VIRGINIA — Pathogenesis of the concentric hypertrophy of the kidney arteriolesUniversity of Virginia

DK grant. $797,878. PI: ROBERTO Ariel GOMEZ

full page →nih reporter ↗

Feb 24, 2026grant187d agoUNIVERSITY OF CALIFORNIA SANTA CRUZ — The multifaceted pathways of astrovirus entry and egress

GM grant. $422,677. PI: Valerie Cortez

full page →nih reporter ↗

page 435 of 475